FIELD: biotechnology.
SUBSTANCE: disclosed are methods of treating or inhibiting tumour growth, including type 2 immune-dependent malignant growth, wherein the methods comprise selecting and administering to an individual in need thereof a therapeutically effective amount of an antibody specifically binding the IL-4 receptor (IL-4R), and a therapeutically effective amount of an antibody specifically binding programmed death protein 1 (PD-1).
EFFECT: invention promotes tumour regression, inhibits tumour growth, reduces the tumour load and/or prevents tumour recurrence in the patient.
43 cl, 12 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND IMMUNE CONTROL POINT INHIBITOR | 2020 |
|
RU2828377C1 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| IL-18-BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASES | 2016 |
|
RU2755691C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
